ClinicalTrials.gg
CompletedNCT01329796PLEASEUpdated Apr 6, 2011

Pertubation With Lignocaine in Endometriosis

A Phase 2 interventional study of Lignocaine and Ringers Solution in Endometriosis and Dysmenorrhea, sponsored by Isifer AB. Completed at 3 sites in Sweden. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2011-04-06.

Sponsored by Isifer AB · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Endometriosis with a site in Sweden — 6 open to participants now, 6 under way, none of them phase 3. Endometriosis · Sweden.

Enrollment
7th of 11
42 · median 80
Started
2007
the only one that year
Phase 2
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
Isifer AB

Among the 14 studies in Endometriosis with a site in Sweden, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 2, and was the 2nd registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

6 of the 14 studies in Endometriosis with a site in Sweden are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Endometriosis with a site in Sweden, or all of them as a file.
02

Study summary

Endometriosis is a disease of unknown aetiology that can cause severe dysmenorrhea. An altered immune system with elevated levels of cytokines in the peritoneal fluid as well as increased density of nerve fibres, might explain the pathophysiology of dysmenorrhea in endometriosis patients. Lignocaine has anti-inflammatory properties and exerts effect on nerve endings and intra peritoneal macrophages. Pertubation with lignocaine might represent an alternative treatment for endometriosis related dysmenorrhea and avoids the side-effects related to hormonal treatments. A double blind randomized clinical trial, was carried out to evaluate pertubation with lignocaine as a therapy for dysmenorrhea.

03

Conditions studied

  • Endometriosis
  • Dysmenorrhea

Keywords

  • dysmenorrhea,
  • pelvic pain
  • dyspareunia
  • endometriosis
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 20 years
  • endometriosis verified by laparoscopy
  • dysmenorrhea or pelvic pain defined as a pain-score of >50 mm (VAS)
  • normal Fallopian tubes
  • regular menstrual cycles 21-35 days
  • treatment with oral (OC) ongoing > 1 month and continued during the trial
  • previous hormonal treatment discontinued > 1 month (OC, gestagens) and > 6 months (GnRH)
  • no wish for pregnancy during the study
  • normal Pap-smear
  • negative Chlamydia-test
  • negative pregnancy-test
  • given and signed

Exclusion criteria

Exclusion Criteria:

  • Continuous treatment with medication that may increase risk for infection - clinical signs of pelvic inflammatory disease
  • hyperreactivity to local anesthesia
  • fibroids > 2 cm
  • ongoing treatment with GnRH-analog
  • ongoing continuous treatment with high dose gestagens
  • pregnancy
  • peritubal adhesions
  • occluded Fallopian tubes
  • inability to understand information or comply with the study procedures
  • participation in a clinical study within one year before the present study
  • any disease or laboratory finding considered of importance by the investigator not to include the patient
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Pertubation with Endole® (lignocaine)

    Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

    Drug: Lignocaine

  • Placebo comparator
    Placebo

    Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

    Drug: Ringers Solution

Interventions

  • Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

    Also known as: Lidocaine

  • DrugRingers Solution

    Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

06

What researchers measure

Primary outcomes

  1. Pain-questionnaire (validated for endometriosis) supplemented with VAS-scale.

    The pain-questionnaire will be filled out: first time during the first period after inclusion in the study (1st menstruation prior to study treatments=baseline for evaluation) and thereafter during 2nd, 3rd, 4 th, 7th, 10th and 13th menstrual periods.

    Time frame: After three pertubations

Secondary outcomes

  1. Quality of life-questionnaire (validated), EHP-30

    The Quality of life-questionnaire will be filled out: first time during the first period after inclusion in the study (1st menstruation prior to study treatment=baseline for evaluation) and thereafter during 7th and 13th menstrual period.

    Time frame: At the 7th menstruation i.e. after approximately 6 months.

07

Study locations

3 sites
  • Läkargruppen Victoria Söderhallarna 120
    Stockholm, 118 72, Sweden
  • Karolinska Institute, Fertility Unit, K59 Karolinska University Hospital at Huddinge
    Stockholm, 141 86, Sweden
  • Department of Gynaecology and Obstetrics Danderyd Hospital
    Stockholm, 182 88, Sweden
08

References and documents

Publications

  • Wickstrom K, Edelstam G. Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis. Sex Reprod Healthc. 2017 Oct;13:35-40. doi: 10.1016/j.srhc.2017.05.004. Epub 2017 May 25. PubMed 28844356 ↗
  • Wickstrom K, Spira J, Edelstam G. Serum concentration of lignocaine after pertubation: an observational study. Drugs R D. 2013 Sep;13(3):235-9. doi: 10.1007/s40268-013-0022-8. PubMed 23921822 ↗
  • Wickstrom K, Bruse C, Sjosten A, Spira J, Edelstam G. Pertubation with lignocaine as a new treatment of dysmenorrhea due to endometriosis: a randomized controlled trial. Hum Reprod. 2012 Mar;27(3):695-701. doi: 10.1093/humrep/der434. Epub 2012 Jan 9. PubMed 22232129 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jun 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2011
First posted
Apr 6, 2011
Start
Mar 2007
Primary completionActual
Jun 2009
CompletionActual
Mar 2010
Last update
Apr 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01329796
Lead sponsor
Isifer AB
Collaborators
Region Stockholm
First posted
Apr 6, 2011
Start date
Mar 2007
Primary completion
Jun 2009
Completion
Mar 2010
Last update
Apr 6, 2011

Study contacts

Karin Wickström, MD
principal investigator · Danderyd Hospital, SE-182 88 Stockholm, Sweden
Greta Edelstam, MD
study director · Karolinska University Hospital at Huddinge SE-141 86 Stockholm, Sweden

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion